Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Breast and Ovarian Cancer Gene Patents Invalidated by US Supreme Court

By BiotechDaily International staff writers
Posted on 26 Jun 2013
On June 13, 2013, the US Supreme Court (Washington DC, USA) unanimously invalidated patents on two genes tied to ovarian and hereditary breast cancer in response to a lawsuit filed by the American Civil Liberties Union (ACLU; New York, NY, USA) and the Public Patent Foundation (PUBPAT; New York, NY, USA) on behalf of genetic counselors, patients, researchers, breast cancer and women’s health groups, and medical professional associations representing 150,000 geneticists, pathologists, and laboratory specialists.

The patents allowed Myriad Genetics (Salt Lake City, UT, USA) to control access to the genes, known as breast cancer1 (BRCA1) and BRCA2, thus giving them the right to restrict others from doing diagnostic or research testing of the genes, which can be crucial for individuals making important medical decisions. The patents also allowed Myriad to set the terms and cost of testing and made it hard for women to gain access to alternate testing or acquire a comprehensive second opinion about their test findings.

“Today, the court struck down a major barrier to patient care and medical innovation,” said Sandra Park, senior staff attorney with the ACLU Women’s Rights Project. “Myriad did not invent the BRCA genes and should not control them. Because of this ruling, patients will have greater access to genetic testing and scientists can engage in research on these genes without fear of being sued.”

The court found that the patents on human genes are invalid, which represents a vital shift in patent law and overturns current Patent Office policy. The court also found that patents on complementary DNA (cDNA), are patent-eligible. Scientists can provide genetic testing without relying on cDNA. Thus, the court’s ruling lifted the patent hurdle to offering genetic diagnostic testing.

“The court rightfully found that patents cannot be awarded for something so fundamental to nature as DNA,” said Daniel B. Ravicher, executive director of PUBPAT and co-counsel in the lawsuit.

A US federal district court invalidated all of the challenged patents in 2010. In 2012, for the second time, a US federal appeals court ruled that the patents on the genes were lawful. Its 2-1 decision followed a Supreme Court order directing the appeals court to reconsider its initial decision in light of a related patent case decided by the Supreme Court the spring of 2012.

Related Links:

American Civil Liberties Union
Public Patent Foundation
Myriad Genetics



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.